Case Study
Randomizing the First Participant and Reaching 110% of Goal for an Alzheimer’s Study
Tekton supported a one-site Alzheimer’s disease trial led by a recently trained and onboarded new-to-Tekton Principal Investigator. Tekton also consulted on study design and implementation. The site randomized the study’s first participant, reached 110% of its enrollment goal, and became one of the study’s top enrollers.
- 110% of total enrollment goal met
- First participant randomized in the study
- Tekton was one of the study’s top enrollers
About This Study
CLIENT
Biotech
TRIAL
Alzheimer’s disease
TEKTON COVERAGE
One site